


UpToDate recommendations* for pneumococcal vaccination in immunocompromised† adults (≥ 19 years) in the United States



PCV13: 13-valent pneumococcal conjugate vaccine (Prevnar 13); PPSV23: 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23).

* UpToDate's recommendations differ from those of the United States Advisory Committee on Immunization Practices (ACIP). Refer to the UpToDate topic on pneumococcal vaccination in adults for additional information.

† Immunocompromising conditions that are indications for pneumococcal vaccination are:

- Congenital or acquired immunodeficiency (including B or T lymphocyte deficiency, complement deficiencies, and phagocytic disorders excluding chronic granulomatous disease)
- HIV infection
- Hematologic malignancy (eg, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma)
- Solid organ transplantation
- Iatrogenic immunosuppression (including long-term systemic glucocorticoids or radiation)
- Chronic kidney disease
- Nephrotic syndrome

These recommendations do not apply to hematopoietic cell transplant (HCT) recipients, patients with anatomic or functional asplenia, or patients with a cochlear implant or cerebrospinal fluid (CSF) leak in

the absence of an immunocompromising condition. Refer to the relevant UpToDate topics for recommendations regarding these other patient groups.

Δ Only a single dose of PCV13 is indicated during adulthood.

◊ The ACIP recommends a dose of PPSV23 at or after 65 years of age but does not recommend additional doses of PPSV23 every 10 years thereafter; in contrast, UpToDate recommends such revaccination.

Reference: Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.

Graphic 107906 Version 3.0